Pfizer Inc (Pfizer) has completed an extensive review of its global manufacturing network following its acquisition of Wyeth and is consolidating its manufacturing operations. As part of this consolidation decision, PharmaBioSource, Inc. is advising Pfizer on the divestiture of three of its facilities in Puerto Rico. This page outlines the various divestment opportunities.

Oral Dosage Manufacturing Operation with High Containment & Controlled Substances Capabilities		Parenteral Fill / Finish Manufacturing Operation with Lyophilization		Solid Dosage Manufacturing Site with High Containment and Controlled Substances Capabilities		Charlie Shafran Project Leader Cell: 917.821.7693 cshafran@pharmabiosource.com Bill Wiederseim Technical Information Cell: 610.888.9806 wiederseim@pharmabiosource.com Olga Ventura Technical Information Cell: 484.459.4943 oventura@pharmabiosource.com
Go to the Facility Website View the Spec Sheet		Go to the Facility Website View the Spec Sheet		Go to the Facility Website View the Spec Sheet